These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 32576444)

  • 1. Chr2 30297612-ALK, A Novel Intergenic Fusion With Exon18 of ALK, Responds to Crizotinib.
    Chen X; Zhao G; Zhong P; Zhang M; Chen R; Zhang D
    Clin Lung Cancer; 2020 Nov; 21(6):e564-e566. PubMed ID: 32576444
    [No Abstract]   [Full Text] [Related]  

  • 2. Coexistence of a Novel PRKCB-ALK, EML4-ALK Double-Fusion in a Lung Adenocarcinoma Patient and Response to Crizotinib.
    Luo J; Gu D; Lu H; Liu S; Kong J
    J Thorac Oncol; 2019 Dec; 14(12):e266-e268. PubMed ID: 31757376
    [No Abstract]   [Full Text] [Related]  

  • 3. A Novel Intergenic Region between CENPA and DPYSL5-ALK Exon 20 Fusion Variant Responding to Crizotinib Treatment in a Patient with Lung Adenocarcinoma.
    Fei X; Zhu L; Zhou H; Qi C; Wang C
    J Thorac Oncol; 2019 Sep; 14(9):e191-e193. PubMed ID: 31445731
    [No Abstract]   [Full Text] [Related]  

  • 4. Next-generation Sequencing Identified a Novel WDPCP-ALK Fusion Sensitive to Crizotinib in Lung Adenocarcinoma.
    He Z; Wu X; Ma S; Zhang C; Zhang Z; Wang S; Yu S; Wang Q
    Clin Lung Cancer; 2019 Sep; 20(5):e548-e551. PubMed ID: 31281052
    [No Abstract]   [Full Text] [Related]  

  • 5. The clinical responses of TNIP2-ALK fusion variants to crizotinib in ALK-rearranged lung adenocarcinoma.
    Feng T; Chen Z; Gu J; Wang Y; Zhang J; Min L
    Lung Cancer; 2019 Nov; 137():19-22. PubMed ID: 31521978
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel NLRC4-ALK and EML4-ALK double fusion mutations in a lung adenocarcinoma patient: A case report.
    Wu X; Wang W; Zou B; Li Y; Yang X; Liu N; Ma Q; Zhang X; Wang Y; Li D
    Thorac Cancer; 2020 Jun; 11(6):1695-1698. PubMed ID: 32212216
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A novel SOS1-ALK fusion variant in a patient with metastatic lung adenocarcinoma and a remarkable response to crizotinib.
    Chen HF; Wang WX; Xu CW; Huang LC; Li XF; Lan G; Zhai ZQ; Zhu YC; Du KQ; Lei L; Fang MY
    Lung Cancer; 2020 Apr; 142():59-62. PubMed ID: 32114282
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Coexistence of a novel RGS18 downstream intergenic region ALK fusion and a THUMPD2-ALK fusion in a lung adenocarcinoma patient and response to crizotinib.
    Wang YL; Wu ZZ; Zhang HR; Chen DS; Zhao X
    Lung Cancer; 2021 Apr; 154():216-218. PubMed ID: 33637344
    [No Abstract]   [Full Text] [Related]  

  • 9. Melanoregulin-Anaplastic Lymphoma Kinase (ALK), a Novel ALK Rearrangement That Responds to Crizotinib in Lung Adenocarcinoma.
    Wang L; Yao S; Teng L; Zhang W; Chen L
    J Thorac Oncol; 2020 Mar; 15(3):e44-e46. PubMed ID: 32093861
    [No Abstract]   [Full Text] [Related]  

  • 10. Attenuated isolated 3' signal: A highly challenging therapy relevant ALK FISH pattern in NSCLC.
    Smuk G; Pajor G; Szuhai K; Morreau H; Kocsmár I; Kocsmár É; Pajor L; Kajtár B; Sárosi V; Lotz G; Tornóczky T
    Lung Cancer; 2020 May; 143():80-85. PubMed ID: 32272316
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Complete Pathological Response to Crizotinib in a Patient with ALK-rearranged Lung Adenocarcinoma.
    Mattar MS; Chang J; Benayed R; Halpenny D; Powers A; Kleiner DE; Drilon A; Kris MG
    Clin Lung Cancer; 2020 Jan; 21(1):e25-e29. PubMed ID: 31690489
    [No Abstract]   [Full Text] [Related]  

  • 12. A novel SETD3-ALK fusion in lung adenocarcinoma and sustained clinical response to crizotinib.
    Dai S; Liu XQ; Wu Q; Du CM; Liu Q; Xue YY; Luo F; Li Y
    Lung Cancer; 2023 Jan; 175():121-124. PubMed ID: 36495785
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CUX1-ALK, a Novel ALK Rearrangement That Responds to Crizotinib in Non-Small Cell Lung Cancer.
    Zhang M; Wang Q; Ding Y; Wang G; Chu Y; He X; Wu X; Shao YW; Lu K
    J Thorac Oncol; 2018 Nov; 13(11):1792-1797. PubMed ID: 30010043
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Detection of known and novel ALK fusion transcripts in lung cancer patients using next-generation sequencing approaches.
    Vendrell JA; Taviaux S; Béganton B; Godreuil S; Audran P; Grand D; Clermont E; Serre I; Szablewski V; Coopman P; Mazières J; Costes V; Pujol JL; Brousset P; Rouquette I; Solassol J
    Sci Rep; 2017 Oct; 7(1):12510. PubMed ID: 28970558
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of a Novel MET Exon 14 Skipping Variant Coexistent with EGFR Mutation in Lung Adenocarcinoma Sensitive to Combined Treatment with Afatinib and Crizotinib.
    Zeng L; Xia C; Zhang Y; Yang N
    J Thorac Oncol; 2019 Apr; 14(4):e70-e72. PubMed ID: 30922580
    [No Abstract]   [Full Text] [Related]  

  • 16. Rare coexistence of three novel CDCA7-ALK, FSIP2-ALK, ALK-ERLEC1 fusions in a lung adenocarcinoma patient who responded to Crizotinib.
    Zhao G; Chen L; Xiao M; Yang S
    Lung Cancer; 2021 Feb; 152():189-192. PubMed ID: 33419583
    [No Abstract]   [Full Text] [Related]  

  • 17. MPRIP-ALK, a Novel ALK Rearrangement That Responds to ALK Inhibition in NSCLC.
    Fang W; Gan J; Hong S; Lu F; Zhang L
    J Thorac Oncol; 2019 Jul; 14(7):e148-e151. PubMed ID: 31235041
    [No Abstract]   [Full Text] [Related]  

  • 18. A novel HIP1-ALK fusion variant in lung adenocarcinoma showing resistance to Crizotinib.
    Li M; Tang Q; Chen S; Wang Y
    Lung Cancer; 2021 Jan; 151():98-100. PubMed ID: 33280926
    [No Abstract]   [Full Text] [Related]  

  • 19. A rare double ALK fusion variant EML4-ALK and CDK15-ALK in lung adenocarcinoma and response to crizotinib: A case report.
    Guo J; Shi J; Yao M; Jin Y; Liu D; Liu W; Wang K; Jiang D
    Medicine (Baltimore); 2020 Nov; 99(45):e22631. PubMed ID: 33157918
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting SLMAP-ALK-a novel gene fusion in lung adenocarcinoma.
    Pagan C; Barua S; Hsiao SJ; Mansukhani M; Saqi A; Murty V; Fernandes H
    Cold Spring Harb Mol Case Stud; 2019 Jun; 5(3):. PubMed ID: 31160357
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.